Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO® (berotralst
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Wednesday, 21'st Feb 2024
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the TD Cowen 44th Annual Health Care Con
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of r
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
10:31am, Tuesday, 09'th Jan 2024
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely
06:34pm, Thursday, 14'th Dec 2023
BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and Bifunc
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Tuesday, 21'st Nov 2023
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx C
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO�
BioCryst to Report Third Quarter 2023 Financial Results on November 2
07:00am, Thursday, 19'th Oct 2023
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?
11:18am, Tuesday, 19'th Sep 2023
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment
10:53am, Monday, 18'th Sep 2023
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d'excellence en santé et services sociaux (INESSS) has issued a positiv
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Wednesday, 23'rd Aug 2023
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2023 Wells Fargo Healthcare Conferen
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript
12:55pm, Thursday, 03'rd Aug 2023
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer A
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
09:48am, Thursday, 03'rd Aug 2023
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.32 per share a year ago.
BioCryst to Report Second Quarter 2023 Financial Results on August 3
07:00am, Thursday, 20'th Jul 2023
RESEARCH TRIANGLE PARK, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on
BioCryst to Present at Upcoming Investor Conference
07:00am, Thursday, 01'st Jun 2023
RESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies Healthcare Conference on W
